• 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Blood and Lymphatic Cancer: Targets and Therapy >Harnessing the immune system through programmed death-1 blockade in the management of Hodgkin lymphoma
【24h】

Harnessing the immune system through programmed death-1 blockade in the management of Hodgkin lymphoma

机译：在霍奇金淋巴瘤的治疗中通过程序性死亡1阻断来利用免疫系统

获取原文
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Immunotherapy is a rapidly evolving therapeutic option in the treatment of lymphoma. Neoplastic cells evade immune recognition through the programmed death (PD)-1/PD-ligand immune checkpoint pathway. Several novel agents have been developed to restore the immune system’s ability to recognize and destroy cancer cells. Nivolumab and pembrolizumab are two anti-PD-1 antibodies that have demonstrated success in the treatment of refractory Hodgkin lymphoma. Harnessing the immune system’s ability to target neoplastic cells, ideally without the use of cytotoxic chemotherapeutic agents, is one way in which these novel agents are changing the therapeutic landscape in the treatment of lymphomas. Here, we review the emerging data regarding checkpoint inhibitors in the management of Hodgkin lymphoma, the unique adverse effects encountered with the use of these agents, and a practical approach to the management of these adverse effects. Additionally, we discuss upcoming trials that will further assess the promising future developments of checkpoint inhibition in the treatment of not only Hodgkin lymphoma but also other B cell lymphomas and myeloma. These agents offer immense promise of a future where many lymphomas can be treated without the toxic effects of chemotherapeutic agents.
机译：免疫疗法是治疗淋巴瘤的快速发展的治疗选择。肿瘤细胞通过程序性死亡（PD）-1 / PD-配体免疫检查点途径逃避免疫识别。已经开发出几种新型试剂来恢复免疫系统识别和破坏癌细胞的能力。 Nivolumab和pembrolizumab是两种抗PD-1抗体，已在治疗难治性霍奇金淋巴瘤中取得成功。利用免疫系统靶向肿瘤细胞的能力（理想情况下不使用细胞毒性化学治疗剂）是这些新型药物改变淋巴瘤治疗前景的一种方式。在这里，我们回顾了有关霍奇金淋巴瘤治疗中检查点抑制剂的新兴数据，使用这些药物所遇到的独特不良反应以及管理这些不良反应的实用方法。此外，我们讨论了即将进行的试验，这些试验将进一步评估检查点抑制在霍奇金淋巴瘤以及其他B细胞淋巴瘤和骨髓瘤治疗中的有希望的未来发展。这些试剂为将来可以治疗许多淋巴瘤而无化疗剂的毒性作用提供了广阔的前景。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号